English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Lenalidomide is a 2nd generation immunomodulatory drug (IMiD) that has shown remarkable activity in the treatment of multiple myeloma (MM). In comparison with its parent drug thalidomide, lenalidomide has the advantage of having no neurological toxicity.Two phase III randomized studies validated

Lenalidomide in the treatment of plasma cell dyscrasia: state of the art and perspectives